Navigation Links
A new radiotherapy technique significantly reduces irradiation of healthy tissue
Date:2/24/2012

This release is available in Spanish.

Researchers at the University of Granada and the university hospital Virgen de las Nieves in Granada have developed a new radiotherapy technique that is much less toxic than that traditionally used and only targets cancerous tissue.

This new protocol provides a less invasive but equally efficient cancer postoperative treatment for cases of cancer of the oral cavity and pharynx.

The study -conducted between 2005 and 2008- included 80 patients diagnosed with epidermoid cancer of the oral cavity and pharynx, who had undergone lymph node removal. The affected nodes were located by the surgeon during the intervention and classified into different risk levels. Classification allowed physicians to target the areas at a higher risk of recurrence. This way, neck areas at a lower risk of containing residual cancer cells were not irradiated. Researchers achieved both to minimize the side effects of radiotherapy, and to reduce treatment discontinuation, thus achieving the therapy to be more effective.

A Highly Toxic Treatment

Over 70% of oral and pharynx cancer treated with surgery require supplementary treatment with radiotherapy occasionally associated to chemotherapy, because of the high risk for recurrence and spread through the lymph nodes. Radiotherapy and chemotherapy are highly toxic, mainly due to the ulceration of the mucous membranes lining the oral cavity; toxicity leads may patients to stop the treatment, which significantly reduces the chances of cure.

By using the risk map obtained with the collaboration of the surgeon and the pathologist, an individualized treatment was designed and adapted to the specific risk level of recurrence in each neck area. The volume of tissue irradiated was significantly smaller than that usually irradiated with traditional techniques.

This trial was led by the radiation oncologist at the university hospital Virgen de las Nieves, Miguel Martnez Carrillo, and conducted in collaboration with the Services of Radiation Oncology, Medical Physics, Maxillofacial Surgery and Pathology of the university hospital Virgen de las Nieves, and the University of Granada Department of Radiology and Physical Medicine

After a three-year follow up, using this new technique, scientists achieved to reduce the volume of irradiated tissue in 44% of patients. By this new technique, irradiation of an average volume of 118 cc of tissue was avoided. A total of 95% of patients completed radiotherapy and presented significantly lower toxicity than patients treated with the traditional technique. Recurrence rates did not increase.

This study was coordinated by University of Granada professors Rosario del Moral vila and Jos Mariano Ruiz de Almodvar Rivera. The results of this study will be published in the next issue of the journal Radiation Oncology.


'/>"/>

Contact: Miguel Martnez Carrillo
martinezcarrillo.miguel@gmail.com
34-651-489-745
University of Granada
Source:Eurekalert

Related medicine news :

1. Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy
2. Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence
3. Combination of existing safety checks could greatly reduce radiotherapy errors
4. Sensitizing prostate cancer to radiotherapy
5. ASTRO publishes evidence-based guideline for thoracic radiotherapy
6. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
7. BUSM study shows chemoradiotherapy prior to surgery improves survival
8. ASTRO publishes palliative radiotherapy for bone metastases guideline
9. Stereotactic radiotherapy slows pancreatic cancer progression for inoperable patients
10. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
11. Well-tolerated radiotherapy provides longer life to patients with recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... , ... “The Land of More and More”: a brilliant story for ... shares the simple and achievable answer. “The Land of More and More” is the ... Church in Angola, Indiana where he works with the children’s ministry department. , ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the ... needs of over 30 million. Many interviews with Dr. Carol Francis at the Los ... were suppose to prioritize. Interviews provided below. , Among those present was ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... innovators, engineers, and scientists from around the world, announces the launch of its ... quick and easy portal to research breakthroughs and trending news, vital information on ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and ... has been condensed to a single page, maximizing usability and improving efficiency significantly ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology: